More than 90 percent of patients with chronic myelogenous leukemia (CML) carry a chromosomal abnormality, termed bcr-abl, that is important in the pathogenesis of the disease. Identification of this chromosomal abnormality is significant in the initial diagnosis of these patients and in following their course after treatment. Messenger RNA is isolated from their peripheral blood and reverse transcribed, and identification of bcr-abl is done on the cDNA using a nested polymerase chain reaction strategy and specific primers followed by gel electrophoresis. Approximately 70 studies have been performed on patients with CML. This project is completed and has been transferred as a """"""""routine"""""""" test to the main hematology laboratory, with the need for approval by the senior staff.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL010301-02
Application #
6431864
Study Section
Cell Biology Integrated Review Group (CB)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code